Metraipolis › archive › dc_8b625ea237fc

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis — Europe PMC PMID:42180761

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42180761
DOI
10.3389/fmed.2026.1803727
License (as archived)
solo-consultazione
Archived
2026-11-02T15:46:33.199Z
SHA-256 of the archived text
cc9c1ca60c44f6ff213d16e6b4e58a3fd07714bab0be4bb2c4e86221749ad5cb
Stable URL of this page
https://metraipolis.com/documento/dc_8b625ea237fc

How to cite

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis — Europe PMC PMID:42180761 — Europe PMC (en), https://europepmc.org/article/MED/42180761 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8b625ea237fc (Metraipolis archive dc_8b625ea237fc, sha256 cc9c1ca60c44f6ff213d16e6b4e58a3fd07714bab0be4bb2c4e86221749ad5cb)
BibTeX
@misc{dc8b625ea237fc,
  title = {Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis — Europe PMC PMID:42180761},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42180761},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8b625ea237fc; sha256 cc9c1ca60c44f6ff213d16e6b4e58a3fd07714bab0be4bb2c4e86221749ad5cb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42180761. Agents can read the archived copy with the MCP tool read_document.